Filing Analysis
📄 Other SEC Filing
Filed Jun 01, 2026
⚪ LOW
NextCure announced Phase 1 dose escalation data for its drug candidate SIM0505 at the ASCO 2026 conference, showing an objective response rate (ORR) of 55% in gynecologic cancer patients. The company also provided a liquidity update, stating cash is sufficient to fund operations into Q1 2027.
🚩 Red Flags
- Three patients required dose discontinuation due to severe adverse events, including Grade 2 Interstitial Lung Disease (ILD) and Grade 4 thrombocytopenia.
📋 Key Facts
- Phase 1 study (NCT06792552) included 59 patients across the US (n=25) and China (n=34).
- Gynecologic cancer patients (n=20) in the 4.8-8.0 mg/kg dose range showed an ORR of 55% (11/20).
- Ovarian cancer patients showed a 52.9% ORR (9/17) and USC patients showed a 66.7% ORR (2/3).
- Safety profile: Grade 3/4 TEAEs were predominantly hematological; three patients discontinued treatment due to Grade 2 ILD, Grade 3 fungal pneumonia, and Grade 4 thrombocytopenia.
- Cash runway is estimated to last into the first quarter of 2027.
📢 Regulation FD Disclosure
Filed May 07, 2026
⚪ LOW
NextCure, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly update on the company's operations and financial condition.
📋 Key Facts
- Reported financial results for the quarter ended March 31, 2026.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
- Included Exhibit 99.1, a press release dated May 7, 2026.
- The information is furnished and not deemed 'filed' for Section 18 purposes.
📄 Other SEC Filing
Filed Mar 05, 2026
⚪ LOW
NextCure, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 5, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1 to the filing.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.